HIV care in Istanbul, Turkey: How far is it from the UNAIDS 90–90–90 targets?
- 15 November 2019
- journal article
- research article
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 30 (13) , 1298-1303
Abstract
The prevalence of human immunodeficiency virus (HIV) infection is low but it is steadily increasing in Turkey. In the current study, we aimed to assess the status of HIV infection management with the proposed 90–90–90 targets in a large HIV cohort in Istanbul, Turkey. The cohort included 2382 patients (2082 male, 300 female, mean age was 36.3 ± 11.3 years). Mean CD4 cell count was 399 cells/mm3 and HIV-RNA level was 576,235 copies/ml. According to the modeling by the Modeling tool of European Center for Diseases Control Software, 72 and 74% of all HIV patients had been diagnosed in 2016 and 2017, respectively (the first target). Among 2382 patients, 2191 (92%) were on antiretroviral therapy (the second target). The third target of virally suppressing those on treatment was achieved among 70.2% of the patients. The current study suggests that both the fraction of those living with undiagnosed HIV and the proportion of those on treatment who are virally suppressed should be targeted to sustain optimal HIV care. Efforts should continue to surpass the targets of 90–90–90.Keywords
This publication has 20 references indexed in Scilit:
- Estimating HIV Incidence, Time to Diagnosis, and the Undiagnosed HIV Epidemic Using Routine Surveillance DataEpidemiology, 2015
- Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in EuropeJournal of Antimicrobial Chemotherapy, 2015
- Outcomes of initial antiretroviral treatment (ART) among recently diagnosed HIV patients in HIV‐TR cohort, 2011–2012Journal of the International AIDS Society, 2014
- Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assayJournal of Antimicrobial Chemotherapy, 2014
- The cascade of care in the Eastern European country of GeorgiaHIV Medicine, 2014
- Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adultsAIDS, 2014
- Cohort Profile: Seek and Treat for the Optimal Prevention of HIV/AIDS in British Columbia (STOP HIV/AIDS BC)International Journal of Epidemiology, 2014
- Controlling the HIV Epidemic with AntiretroviralsJournal of the International Association of Providers of AIDS Care (JIAPAC), 2013
- The Spectrum of Engagement in HIV Care and its Relevance to Test-and-Treat Strategies for Prevention of HIV InfectionClinical Infectious Diseases, 2011
- Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1–Infected Adults: 48-Week Results From the ASSERT StudyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010